Senolytic Agents Clear Senescent Foam Cells to Stabilize Atherosclerotic Plaques
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Atherosclerosis, characterized by the formation of unstable atherosclerotic plaques in arteries, poses a significant risk for cardiovascular events due to the inability of existing technologies to effectively clear senescent cells that drive plaque growth and instability.
Innovation Solution
Administration of senolytic agents, such as Nutlin-3a or ABT263, which selectively kill senescent cells, thereby reducing plaque burden and stabilizing existing plaques by eliminating p16Ink4a-positive cells from atherosclerotic lesions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If senescent cells are not cleared from atherosclerotic plaques, then plaque growth continues and instability increases, but existing technologies cannot effectively clear these cells
Solution Approach 1:
The patent applies the extraction principle by selectively removing senescent cells from atherosclerotic plaques using senolytic agents. The invention extracts the harmful senescent cell population from the plaque tissue through targeted cell death mechanisms, thereby eliminating the source of plaque instability and growth without affecting other plaque components or healthy cells.
Solution Approach 2:
The patent employs parameter changes by altering the physiological state of senescent cells through senolytic treatment. The senolytic agents induce specific cellular parameter changes that lead to senescent cell death, transforming the stable but harmful senescent cell population into a cleared state, thereby improving plaque stability.
2Object-affected harmful factors
If senescent cells accumulate in plaques, then plaque burden increases and cardiovascular events are more likely, but no effective clearance method exists
Solution Approach 1:
The patent extracts senescent cells from the plaque environment using senolytic agents that specifically target and eliminate these cells. This extraction process reduces the quantity of senescent cells in plaques, thereby decreasing the harmful factors that lead to cardiovascular events while maintaining the integrity of other plaque components.
Solution Approach 2:
The patent introduces senolytic agents as intermediary substances that mediate the clearance of senescent cells. These agents act as intermediaries between the therapeutic goal (reducing senescent cell burden) and the biological system (plaque tissue), enabling selective cell removal without directly affecting healthy cells or plaque structure.
3Stability of the object's composition
If senescent cells are present in plaques, then monocyte recruitment and matrix metalloprotease production are enhanced, but clearing these cells requires selective targeting
Solution Approach 1:
The patent applies local quality by creating selective differentiation between senescent cells and other plaque components. The senolytic agents exhibit local quality specificity, targeting only senescent cells while leaving other plaque elements (such as healthy cells, extracellular matrix, and lipids) unaffected, thereby maintaining plaque composition stability while eliminating harmful factors.
Solution Approach 2:
The senolytic agents serve as intermediary substances that selectively interact with senescent cells through specific molecular mechanisms. These intermediaries bind to or activate pathways unique to senescent cells, inducing their death without disrupting the overall plaque structure or affecting non-senescent cell populations.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The clearance of senescent cells leads to a significant reduction in plaque formation and stabilization of existing plaques, thereby reducing the risk of cardiovascular events like heart attacks and strokes by inhibiting monocyte recruitment and matrix metalloprotease production.
Implementation Method 1
Administration of senolytic agents, such as Nutlin-3a or ABT263, which selectively kill senescent cells
Data Source
AI summary
Foamy macrophages with senescence markers accumulate in the subendothelial space at the onset of atherosclerosis where they drive pathology by increasing expression of key atherogenic and inflammatory cytokines and chemokines. In advanced lesions, senescent cells promote features of plaque instability, including elastic fiber degradation and fibrous cap thinning, by heightening metalloprotease production. This invention provides methods and materials for treating arthritis by removing senescent cells in or around atherosclerotic plaques, thereby stabilizing the plaques, inhibiting rupture of the plaques and pathological sequelae that manifest as coronary artery disease.